LSC
CLDI icon

Logan Stone Capital’s Calidi Biotherapeutics CLDI Stock Holding History

Logan Stone Capital’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-78
Closed -$1.47M – 205
2022
Q3 		$1.47M Buy
+78
New +$1.5M 0.97% 23

Other funds holding CLDI

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
EC
Elequin Capital New York $3.36B AUM 11.23% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return

Logan Stone Capital's CLDI Position: Q4 2022 in Review

Logan Stone Capital sold out of Calidi Biotherapeutics (CLDI) in Q4 2022, closing a stake of 78 shares — an estimated $1.47M sold.

Logan Stone Capital first reported a position in CLDI in Q3 2022 and held it in 1 quarter. The position peaked at $1.47M in Q3 2022. 23 funds tracked by Wall St. Rank hold CLDI as of Q4 2022.

  • Logan Stone Capital reported no remaining Calidi Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Logan Stone Capital sold 78 Calidi Biotherapeutics shares in Q4 2022, an estimated $1.47M.
  • Logan Stone Capital first reported a position in Calidi Biotherapeutics in Q3 2022 and held it in 1 quarter.
  • Logan Stone Capital's Calidi Biotherapeutics position peaked at $1.47M in Q3 2022.
  • 23 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q4 2022.

Based on Logan Stone Capital's 13F filing for Q4 2022, filed 14 Feb 2023.